# Ultragenyx Pharmaceutical Inc.: overview

RARE · Nasdaq · CIK 1515673 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rare.md) · [Financials](/companies/rare/financials.md) · [Filings](/companies/rare/filings.md) · [Insiders](/companies/rare/insiders.md)

Latest reported revenue: [$214.0m](/filings/0001193125-26-333233.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-333233).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [139](/filings/0001193125-25-265126.md) | [165 d](/filings/0001193125-26-057329.md) | [139](/filings/0001193125-26-206960.md) | [167](/filings/0001193125-26-333233.md) | [160](/filings/0001193125-25-265126.md) | [207 d](/filings/0001193125-26-057329.md) | [136](/filings/0001193125-26-206960.md) | [214](/filings/0001193125-26-333233.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(94.6%)](/filings/0001193125-25-265126.md) | [(74.3%) d](/filings/0001193125-26-057329.md) | [(102.9%)](/filings/0001193125-26-206960.md) | [(64.7%)](/filings/0001193125-26-333233.md) | [(106.9%)](/filings/0001193125-25-265126.md) | [(54.7%) d](/filings/0001193125-26-057329.md) | [(124.3%)](/filings/0001193125-26-206960.md) | [(35.0%)](/filings/0001193125-26-333233.md) |
| Net margin | % | [(95.7%)](/filings/0001193125-25-265126.md) | [(80.9%) d](/filings/0001193125-26-057329.md) | [(108.6%)](/filings/0001193125-26-206960.md) | [(68.9%)](/filings/0001193125-26-333233.md) | [(112.8%)](/filings/0001193125-25-265126.md) | [(62.0%) d](/filings/0001193125-26-057329.md) | [(136.0%)](/filings/0001193125-26-206960.md) | [(43.0%)](/filings/0001193125-26-333233.md) |
| Diluted EPS | $ per share | [(1.40)](/filings/0001193125-25-265126.md) | not reported | [(1.57)](/filings/0001193125-26-206960.md) | [(1.17)](/filings/0001193125-26-333233.md) | [(1.81)](/filings/0001193125-25-265126.md) | not reported | [(1.84)](/filings/0001193125-26-206960.md) | [(0.90)](/filings/0001193125-26-333233.md) |
| Free cash flow | $m | [(68.6) d](/filings/0001193125-25-265126.md) | [(79.5) d](/filings/0001193125-26-057329.md) | [(167)](/filings/0001193125-26-206960.md) | [(112) d](/filings/0001193125-26-333233.md) | [(92.2) d](/filings/0001193125-25-265126.md) | [(101) d](/filings/0001193125-26-057329.md) | [(198)](/filings/0001193125-26-206960.md) | [(98.0) d](/filings/0001193125-26-333233.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [351](/filings/0000950170-24-017879.md) | [363](/filings/0000950170-25-023312.md) | [434](/filings/0001193125-26-057329.md) | [560](/filings/0001193125-26-057329.md) | [673](/filings/0001193125-26-057329.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(108.6%)](/filings/0000950170-24-017879.md) | [(178.6%)](/filings/0000950170-25-023312.md) | [(131.1%)](/filings/0001193125-26-057329.md) | [(95.7%)](/filings/0001193125-26-057329.md) | [(79.5%)](/filings/0001193125-26-057329.md) |
| Net margin | % | [(129.2%)](/filings/0000950170-24-017879.md) | [(194.7%)](/filings/0000950170-25-023312.md) | [(139.9%)](/filings/0001193125-26-057329.md) | [(101.6%)](/filings/0001193125-26-057329.md) | [(85.4%)](/filings/0001193125-26-057329.md) |
| Diluted EPS | $ per share | [(6.70)](/filings/0000950170-24-017879.md) | [(10.12)](/filings/0000950170-25-023312.md) | [(8.25)](/filings/0001193125-26-057329.md) | [(6.29)](/filings/0001193125-26-057329.md) | [(5.83)](/filings/0001193125-26-057329.md) |
| Free cash flow | $m | [(412)](/filings/0000950170-24-017879.md) | [(497)](/filings/0000950170-25-023312.md) | [(519)](/filings/0001193125-26-057329.md) | [(421)](/filings/0001193125-26-057329.md) | [(472)](/filings/0001193125-26-057329.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rare/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $355.7m | 10,654,276 |  | Added +3,354,678 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $260.3m | 7,796,895 |  | Added +4,148,100 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $226.7m | 6,790,135 |  | Added +1,404,143 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $214.1m | 6,560,809 |  | Added +1,982,785 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $205.6m | 6,158,766 |  | Added +1,137,325 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $143.5m | 4,296,491 |  | Added +106,660 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $120.9m | 3,621,200 |  | Added +1,415,380 |
| [SANDS CAPITAL MANAGEMENT, LLC](/funds/1020066.md) | 2026-06-30 | $105.5m | 3,158,368 |  | Reduced −56,165 |
| [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $98.2m | 2,939,719 |  | Added +1,508,648 |
| [FRONTIER CAPITAL MANAGEMENT CO LLC](/funds/351173.md) | 2026-06-30 | $95.1m | 2,847,936 |  | Added +656,754 |

## Recent filings

[All 1,135 filings](/companies/rare/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 09:00 ET | [8-K](/filings/0001193125-26-424739.md) | 8.01 Other events | 0001193125-26-424739 |
| 2026-10-14 | 09:00 ET | [8-K](/filings/0001193125-26-421079.md) | 1.01 Entry into a material agreement | 0001193125-26-421079 |
| 2026-10-07 | 09:00 ET | [8-K](/filings/0001193125-26-416251.md) | 1.01 Entry into a material agreement | 0001193125-26-416251 |
| 2026-09-17 | 15:55 ET | [8-K](/filings/0001515673-26-000006.md) | 8.01 Other events | 0001515673-26-000006 |
| 2026-09-02 | 16:04 ET | [8-K](/filings/0001193125-26-380165.md) | 8.01 Other events | 0001193125-26-380165 |
| 2026-08-19 | 17:24 ET | [8-K](/filings/0001193125-26-357185.md) | 8.01 Other events | 0001193125-26-357185 |
| 2026-08-11 | 08:30 ET | [8-K](/filings/0001193125-26-343525.md) | 8.01 Other events | 0001193125-26-343525 |
| 2026-08-05 | 18:07 ET | [10-Q](/filings/0001193125-26-333233.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333233 |
| 2026-08-04 | 16:09 ET | [8-K](/filings/0001193125-26-332802.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332802 |
| 2026-05-18 | 14:15 ET | [8-K](/filings/0001193125-26-228639.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-228639 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-057329.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/81ae755e-06ee-4921-b4cf-40b548679262)

## About the filer

- CIK: 1515673
- Tickers: RARE
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 14:15 ET. No prices; not investment advice.